Contract development and manufacturing organization (CDMO) Capstone Development has announced that its biosimilar version of insulin has received marketing authorization in Europe and Canada.
The Illinois, USA-based company partners with healthcare firms to develop products, using its subsidiaries Celerity Pharmaceuticals, Gage Development and Balmoral Medical.
The new insulin product, the first ready-to-use insulin for IV infusion, received US Food and Drug Administration approval in 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze